Vosoritide is a longer-acting C-type natriuretic peptide (CNP) analog that modulates activity of the fibroblast growth factor receptor 3 (FGFR3) by inhibiting a signaling pathway that mediates its effects, thereby stimulating endochondrial growth, resulting in enhanced growth velocity. It is indicated to increase linear growth in pediatric patients aged ≥ 5 years with achondroplasia and open epiphyses.
If you have a Hayes login, click here to view the full report on the Knowledge Center.